Literature DB >> 22776742

QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis.

Franco Trevisani1, Antonio Di Micoli, Andrea Zambruni, Maurizio Biselli, Valentina Santi, Virginia Erroi, Barbara Lenzi, Paolo Caraceni, Marco Domenicali, Mario Cavazza, Mauro Bernardi.   

Abstract

BACKGROUND & AIMS: QT interval prolongation is frequent in cirrhosis, and stressful conditions could further prolong QT. We aimed to test this hypothesis and, if it proved correct, to assess its prognostic meaning.
METHODS: We reviewed the clinical records of 70 consecutive cirrhotic and 40 non-cirrhotic patients with acute gastrointestinal bleeding. All patients had been evaluated before bleeding (T0) and were re-evaluated at the time of bleeding (T1) and 6 weeks afterwards (T2).
RESULTS: QT corrected by heart rate (QTc) lengthened at T1, returning towards baseline values at T2 (mean ± SEM; from 415.9 ± 4.3 to 453.4 ± 4.3 to 422.2 ± 5.7 ms, P < 0.001) in cirrhotics; contrariwise, QTc did not change in non-cirrhotic patients. The 6-week mortality was 29.6% among cirrhotic patients, while no control patient died. At T1, patients who died had longer QTc (P = 0.001) and higher model of end-stage liver disease (MELD) score (P < 0.001) than survivors. MELD and QTc independently predicted survival. Their areas under the ROC curve were 0.88 (CI 95% 0.78-0.95) and 0.75 (CI 95% 0.63-0.85) respectively; the best cut-off values were MELD ≥20 and QTc ≥ 460 ms. Based on these factors, the 6-week mortality was: 0% for patients without risk factors, 32.1% for those with one risk factor and 70.6% for those with both (P < 0.001).
CONCLUSIONS: Acute gastrointestinal bleeding further prolongs QTc in cirrhosis. This abnormality independently predicts bleeding-induced mortality. The combined measurement of QTc interval and MELD can clearly identify three patient strata at increasing risk of bleeding-related mortality, thus improving the decision-making for these patients.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22776742     DOI: 10.1111/j.1478-3231.2012.02847.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

Review 1.  Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.

Authors:  Pierpaolo Pellicori; Concetta Torromeo; Angela Calicchia; Alessandra Ruffa; Martina Di Iorio; John G F Cleland; Manuela Merli
Journal:  Clin Res Cardiol       Date:  2013-09-01       Impact factor: 5.460

Review 2.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 4.  Arrhythmia risk in liver cirrhosis.

Authors:  Ioana Mozos
Journal:  World J Hepatol       Date:  2015-04-08

5.  Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis.

Authors:  Dimitrios S Karagiannakis; Jiannis Vlachogiannakos; Georgios Anastasiadis; Irini Vafiadis-Zouboulis; Spiros D Ladas
Journal:  Hepatol Int       Date:  2014-06-08       Impact factor: 6.047

6.  Tp-e Interval, Tp-e/QTc Ratio, and Fragmented QRS Are Correlated with the Severity of Liver Cirrhosis.

Authors:  Mehmet Kadri Akboga; Mahmut Yuksel; Kevser Gulcihan Balci; Mustafa Kaplan; Serkan Cay; Volkan Gokbulut; Cagri Yayla; Ahmet Goktug Ertem; Meral Akdogan Ayhan; Serkan Topaloglu; Dursun Aras
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-04-07       Impact factor: 1.468

7.  Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis?

Authors:  Mara Barbosa; Joana Guardado; Carla Marinho; Bruno Rosa; Isabel Quelhas; António Lourenço; José Cotter
Journal:  World J Hepatol       Date:  2016-01-28

8.  Cirrhotic cardiomyopathy: review of pathophysiology and treatment.

Authors:  Maneerat Chayanupatkul; Suthat Liangpunsakul
Journal:  Hepatol Int       Date:  2014-07       Impact factor: 6.047

Review 9.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 10.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.